Na. Cunliffe et al., SEQUENCE-ANALYSIS OF NSP4 GENE OF HUMAN ROTAVIRUS ALLOWS CLASSIFICATION INTO 2 MAIN GENETIC GROUPS, Journal of medical virology, 53(1), 1997, pp. 41-50
The rotavirus nonstructural glycoprotein NSP4 may represent the first
identified viral enterotoxin. We have sequenced reverse transcription-
polymerase chain reaction (RT-PCR)-generated fragments of 16 NSP4 gene
s of human rotavirus (HRV) strains from six different countries, repre
senting seven different G and P type combinations. Based on the amount
of sequence divergence between these and 11 previously sequenced NSP4
genes of human and animal rotaviruses, three distinct genetic groups
could be recognized. Most strains within a group were closely related
to each other at the nucleotide (nt) and amino acid (aa) levels (usual
ly <10% divergence) but more distantly related (maximum 30.0% nt diver
gence and 24.7% aa divergence) to members of the other groups. Intergr
oup variation occurred in two highly variable regions of NSP4 (aa 16-3
4 and aa 131-148). The NSP4 ''toxic peptide'' (aa 114-135) exhibited a
a variation at its carboxy terminus both within and between genetic gr
oups. The largest group (genetic group II) contained HRV strains of su
bgroup II specificity (including genotypes P[8]G1, P[8]G3, P[6]G3, and
P[8]G5 and serotype P8[11]G9), and the smaller group (genetic group I
) contained HRV strains of subgroup I specificity (genotype P[4]G2). T
he NSP4 sequence of the rhesus rotavirus vaccine strain was distinct f
rom all other strains and formed the third group (genetic group III).
The NSP4 genes of animal rotaviruses UK, NCDV, and SA11 (genetic group
I) and YM (genetic group II) and two possible human-animal rotavirus
reassortant strains, Brazilian P[8]G5 and Indian P[11]G9 (genetic grou
p II), could also be classified into one of these groups, suggesting a
close evolutionary relationship between human and animal NSP4 genes.
These results will facilitate studies of the host immune response to N
SP4, which may be relevant to future HRV vaccine design. (C) 1997 Wile
y-Liss, Inc.